Roche expects filing for up to three new molecular entities in 2026, and accelerating its pipeline through partnerships and ...

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to ...

Roche was ranked first for corporate reputation in the field of rare disease by patient groups surveyed for PatientView’s annual report. The Swiss pharma giant topped rivals BioMarin and Amgen, who ...

After a boom during the pandemic, sales from COVID-19 drugs are now nonexistent at Roche. But the Swiss pharma’s blood cancer portfolio is enjoying a rejuvenation. Roche now expects its antibody-drug ...

Roche is expanding its scope to a promising but competitive new obesity target, committing $1.65 billion up front to partner on a clinical-stage Zealand Pharma molecule with the potential to be a ...

Roche Pharma CEO Teresa Graham says that 2026 will be an important year for the company's obesity assets. She says that the ...

Roche’s pharma chief Bill Anderson is embarking on his next assignment outside the company. And the Swiss pharma isn’t really looking elsewhere for his replacement. Roche prefers to lift a company ...

Horizon Therapeutics and Roche rank among the top pharma companies in terms of reputation among rare disease patient groups, according to a recent report compiled by U.K. consultancy PatientView.

In March 2025, The FDA awarded orphan drug designation to Nerlynx® (neratinib) for treating breast cancer patients with brain ...

Agreement allows for a range of potentially best-in-class therapy options as monotherapy and fixed dose combination with Roche`s lead incretin asset CT 388 Collaboration will complement Roche's ...

Combining petrelintide with Roche's dual GLP-1/GIP receptor agonist CT-388 will further strengthen Roche's pipeline in cardiovascular, renal, and metabolic (CVRM) diseases. As a part of the agreement, ...

ZURICH, Dec 12 (Reuters) - Roche (ROG.S), opens new tab said on Monday the head of its pharmaceuticals division had decided to leave after 16 years with the Swiss drugmaker, heralding a wider ...